Comparison of 2-year clinical outcomes with sirolimus and paclitaxel-eluting stents for patients with diabetes: Results of the REgistro regionale AngiopLastiche Emilia-Romagna registry

Catheterization and Cardiovascular Interventions

Volumn 75, Issue 3, 2010, Pages 327-334

  Balducelli, Marco ^a   Ortolani, Paolo ^b   Marzaroli, Paolo ^c   Piovaccari, Giancarlo ^d   Menozzi, Alberto ^e   Manari, Antonio ^f   Sangiorgio, Pietro ^e   Tarantino, Fabio ^g   Rossi, Rosario ^h   Maresta, Aleardo ⁱ   Tondi, Stefano ^j   Passerini, Francesco ^k   Guastaroba, Paolo ^c   Grilli, Roberto ^c   Marzocchi, Antonio ^b  

^a SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Agenzia Sanitaria Regionale   (Italy)

^d OSPEDALE DEGLI INFERMI   (Italy)

^e MAGGIORE HOSPITAL   (Italy)

^f S MARIA NUOVA HOSPITAL   (Italy)

^g MORGAGNI PIERANTONI HOSPITAL   (Italy)

^h UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

ⁱ MARIA CECILIA HOSPITAL   (Italy)

^j Nuovo Ospedale S Agostino   (Italy)

^k Ospedale Civile   (Italy)

more..

Author keywords

Diabetes mellitus; Drug eluting stents; Registries; Restenosis

Indexed keywords

INSULIN; PACLITAXEL; RAPAMYCIN;

AGED; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PARAMETER; REVASCULARIZATION; STENT THROMBOSIS; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG-ELUTING STENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERNET; MALE; MIDDLE AGED; PACLITAXEL; PROPENSITY SCORE; REGISTRIES; RETROSPECTIVE STUDIES; SIROLIMUS;

EID: 77149146804     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.22293     Document Type: Article

References (23)

1. Wilson SR, Vakili BA, Sherman W, Sanborn TA, Brown DL. Effect of diabetes on long-term mortality following contemporary percutaneous coronary intervention: analysis of 4,284 cases. Diabetes Care 2004;27:1137-1142.
2. Sabate M, Jimenez-Quevedo P, Angiolillo DJ, et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: The diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 2005;112:2175-2183.
3. Maresta A, Varani E, Balducelli M, Varbella F, Lettieri C, Sangiorgio P, Biondi Zoccai G; for the DESSERT investigators. Comparison of safety and effectiveness of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian randomized DESSERT study). Am J Cardiol 2008;101:1560-1566.
4. Boyden TF, Nallamothu BK, Moscucci M, et al. Meta-analysis of randomized trials of drug-eluting stents versus bare metal stents in patients with diabetes mellitus. Am J Cardiol 2007;99:1399-1402.
5. Scheen AJ, Warzee F, Legrand VM. Drug-eluting stents: Metaanalysis in diabetic patients. Eur Heart J 2004;25:2167-2168; author reply 2168-2169.
6. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, Von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schomig A. Paclitaxel-or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005;353:663-670.
7. Tomai F, Reimers B, De Luca L, et al. Head-to-head comparison of sirolimus- and paclitaxel-eluting stents in the same diabetic patient with multiple coronary artery lesions: A prospective, randomized, multicenter study. Diabetes Care 2008;31:15-19.
8. Lee S-W, Park S-W, Kim Y-H, et al. Drug eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus. The DECLARE-DIABETES trial (A randomized comparison of triple antiplatelet therapy versus double antiplatelet therapy after drug-eluting stent implantation in diabetic patients). J Am Coll Cardiol 2008;51:1181-1187.
9. Lee S-W, Park S-W, Kim Y-H, et al. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus. J Am Coll Cardiol 2008;52:727-733.
10. Kim J-S, Lee BH, Ko YG, et al.; for the Korean Multicenter Angioplasty Team (KOMATE) investigators. Comparison of sirolimus eluting stent and paclitaxel eluting stent for long-term cardiac adverse events in diabetic patients: The Korean Multicenter Angioplasty Team (KOMATE) registry. Cath Cardiovasc Interv 2008;72:601-607.
11. Ortolani P, Balducelli M, Marzaroli P, et al. Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions. Results from a real-world multicenter registry. Circulation 2008;117:923-930.
12. Stuckley T, Brodie B, Simonton C, et al. Late clinical outcomes of paclitaxel and sirolimus eluting stents in diabetic patients without STEMI: Results from the STENT group, Presentation PCR, Barcelona, 2008.
13. Cox DA, Lasala JM. Two years clinical outcomes following paclitaxel-eluting stent implantation in patients with diabetes. Results from the ARRIVE program, Presentation PCR, Barcelona, 2008.
14. Stankovic G, Cosgrave J, Chieffo A. Impact of sirolimus -eluting and paclitaxel-eluting stents on outcome in patients with diabetes mellitus and stenting in more than one coronary artery. Am J Cardiol 2006;98:362-366.
15. Buch MA, Javaid A, Steinberg D, et al. Outcomes of sirolimusand paclitaxel-eluting stent implantation in patients with insulintreated diabetes mellitus. Am J Cardiol 2008;101:1253-1258.
16. Marzocchi A, Piovaccari G, Manari A, et al. Comparison of effectiveness of sirolimus-eluting stents versus bare metal stents for percutaneous coronary intervention in patients at high risk for coronary restenosis or clinical adverse events. Am J Cardiol 2005;95:1409-1414.
17. Daemen J, Garcia-Garcia HM, Kukreja N, et al. The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J 2007;28: 26-32.
18. Stettler C, Allemann S, Wandel S, et al. Drug eluting and bare metal stents in people with and without diabetes: Collaborative network metanalysis. BMJ 2008;337:1359-1370.
19. Mahmud E, Bromberg-Marin G, Palakodeti V, et al. Clinical ef-ficacy of drug eluting stents in diabetics: A meta-analysis. J Am Coll Cardiol 2008;51:2385-2395.
20. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130.
21. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large twoinstitutional cohort study. Lancet 2007;369:667-678.
22. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159-168.
23. Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40: 373-383.